Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the treatment of patients with advanced, indolent and smoldering systemic mastocytosis (SM), covering anti-mediator and cytotoxic treatments, before highlighting the development of targeted agents. Dr Bose describes the high potency and selectivity of avapritinib and bezuclastinib against mutated KIT kinase, and comments on promising efficacy and safety results from ongoing trials. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
